Beth Faiman
@bethfaiman.bsky.social
📤 158
📥 17
📝 4
Fortunate to speak to colleagues in Brasil / Portuguese about
#MM
and
#CART
,
#bispecifics
. What a unique honor
@mmkingt.bsky.social
about 1 year ago
0
1
0
reposted by
Beth Faiman
Orla McCourt
about 1 year ago
There's very little published on
#rehabilitation
in
#CAR-T
. A short report sharing insights from our service pilot of
#physiotherapy
input before and after CAR-T @UCLH has been published in eJHaem
onlinelibrary.wiley.com/doi/10.1002/...
loading . . .
Single‐centre experience of implementing physiotherapist‐led prehabilitation for chimeric antigen receptor T cell therapy
Introduction This report outlines the evaluation of physiotherapist-led prehabilitation/rehabilitation for recipients of chimeric antigen receptor T (CAR-T) cell therapy. Methods A hybrid approach...
https://onlinelibrary.wiley.com/doi/10.1002/jha2.1006
0
3
2
So happy to have you in Houston at the
#IMF
#myeloma
meeting to kick off!
add a skeleton here at some point
about 1 year ago
0
1
1
reposted by
Beth Faiman
Tracy King
about 1 year ago
Nurse/AH welcome all to join us
@myeloma-society.bsky.social
travel safe - c u in Rio!
events.jspargo.com/ims24/CUSTOM...
0
6
5
reposted by
Beth Faiman
Myeloma Society
about 1 year ago
Don't miss this Meet the Expert session on Saturday, September 28 at
#IMS24
. Register now!➡️
rb.gy/1h136x
0
1
1
T-14 days until
#IMS24
!
@rahulbanerjeemd.bsky.social
add a skeleton here at some point
about 1 year ago
0
1
1
reposted by
Beth Faiman
Rahul Banerjee, MD, FACP
over 1 year ago
1/ And since we can’t tweet during
#IMS24
, also worth highlighting CEPHEUS as another LBA! D-VRd vs VRd in ASCT-ineligible
#MMsm
- large PFS benefit with CD38 addition even if no ASCT. Love simplicity of the last line: ASCT decision-making should not dictate induction choice!
1
5
1
Where are my
#myeloma
peeps?
about 1 year ago
0
6
0
you reached the end!!
feeds!
log in
